Welcome to Listings eXchange, NYSE Euronext's pan-European newsletter dedicated to listed companies in Europe and the entire market...
It took seven weeks into the new year for the Paris IPO market to get going, but what a start it has been. Within a period of six days four new companies listed with their IPO. EOS Imaging, INSIDE Secure and Adocia all listed on NYSE Euronext in Paris. Intrasense joined NYSE Alternext.
INSIDE Secure raised €69 million, which makes it the largest European IPO on NYSE Euronext’s European markets over the last two years. The total amount raised by the four combined has reached a total of €136.4 million.
The Paris listings team has invested a lot of time and effort in informing and attracting companies from the SME segment. The four new Euronext listings can be seen as the continuing results of those efforts. At the official listing ceremony of INSIDE Secure Marc Lefèvre, Head of European Coverage at NYSE Euronext, stated: The great success of this listing also testifies to the exchange’s capacity to offer an outstanding solution to the financing needs of SMEs, which drive economic growth and development in their region,” He added: “Our initiatives are paying off and we hope that the recent revival in listings will continue To that end, NYSE Euronext plans to pursue its efforts to promote and facilitate access to capital markets, and we invite all stakeholders in the market eco-system to join in.”
Today NYSE Euronext announced the members of the new Strategic Planning Committee for SMEs, emphasizing the importance of this segment.
The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system based on the technology that enabled George Charpak to win the Nobel Prize for Physics. The group has obtained authorization to market the system in 30 countries including the United States (FDA), Canada and Australia, as well as countries in the European Union. Thanks to an installed base of 42 sites and more than 150,000 imaging sessions, EOS® is recognized within the international scientific and medical communities. The group posted 2011 sales of €6.9 million and employed 57 people, including an R&D team of 21 engineers, as of 31 December 2011. It has a head office in Paris, a US subsidiary in Cambridge, Massachusetts and offices in Montreal, Canada and Germany.
INSIDE Secure is a major supplier of integrated circuits and embedded software used for secure payments and digital security. The company’s NFC technology, payment solutions and digital security products guarantee the security of a wide range of applications in data management, storage and transmission. Customers serve a wide variety of markets, from mobile payments to ID certification, access control, transport, electronic device manufacturers, pay TV and mobile devices.
A biotech company founded in 2005 by Gérard, Olivier and Rémi Soula (Gérard Soula is the founder of Flamel Technologies), Adocia’s mission is to create best-in-class drugs for the mass market from the innovative formulation of certain already-approved therapeutic proteins. To date, Adocia has carried out two collaborative development programs with Pharma majors. Furthermore, Adocia recently signed an exclusive worldwide license contract with Eli Lilly for the development of an ultrafast insulin analog. As well as the Soula family, which is Adocia’s main shareholder with close to 26% of the company’s capital, Adocia’s shareholders include some of the largest investment funds specializing in innovation: Innobio and Bioam (managed by CDC Entreprises), IdInvest, Amundi, Viveris, Oréo Finance and Sham.
Founded in 2004 and based on innovative technology for detecting tissues with scanner imaging, Intrasense designs, develops and markets Myrian®, a suite of advanced medical software which allows specialists to review and analyze multimodal medical images (IRM, scanner, TEP, X-ray and more). Developed with top partners from the academic world, Myrian® combines and uses all types of medical imaging to extract information essential to patient diagnostics, swift evaluation of the effectiveness of therapies and, by extension, the assessment of drugs undergoing trials for cancer treatments. The software is now used at 300 client sites around the world. Myrian® is a “medical device” certified for use in more than 40 countries including the United States (FDA) and countries in Europe (CE) and Asia. Intrasense has 44 employees, 20 working in Research & Development. The company has been recognized as an “innovative business” by Oseo (France) and has invested over €8 million in R&D since its inception.